Article Text

Download PDFPDF
EP903 Prognostic factors for BRCA mutation in ovarian cancer patients
  1. N Lee1,2,
  2. JH No3 and
  3. YB Kim3
  1. 1Obstetrics and Gynecology
  2. 2CHA Gangnam Medical Center, CHA University, Seoul
  3. 3Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea


Introduction/Background Prognostic factors of BRCA1/2 mutation in epithelial ovarian cancer remain controversial. We retrospectively analyzed prognostic factor of patients with ovarian cancer who underwent BRCA testing at our institute.

Methodology Eighty seven patients who underwent a staging operation for pathologically proven epithelial cancer between February 2006 and August 2017 were enrolled retrospectively. The peripheral germline samples were obtained for BRCA1/2 mutation analysis. Clinico-pathological characteristics were retrospectively reviewed.

Results Frequency of BRCA1/2 mutation was 18.4% in this study. BRCA 1 and BRCA 2 mutations were founded 13.8% (12 cases) and 4.6% (4 cases) of the ovarian cancer patients, respectively. Mutation carriers were diagnosed at a similar age to non-carrier. There was no difference in FIGO stage, histology, grade, lympho-vascular space invasion, lymph-node metastasis, relapse of tumor between the two group. Only gross residual disease was more frequent in mutation group (50% (n=8) versus 22.5% (n=16); p=0.035).

Conclusion BRCA1/2 mutation was not associated with any progression factors. There were more residual masses in mutation carriers. It may be more related to PFS or OS due to residual tumor than mutation itself.

Disclosure The Authors had no conflict of interest in regard to this study.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.